Previous Close | 1.05 |
1-Year Change | -62.09% |
6-Months Change | 26.35% |
3-Months Change | 39.63% |
Moving Avg (50d) | 1.0385 |
Moving Avg (200d) | 0.9903 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 135.1M |
Beta (3-Years) | 1.25 |
Revenue Growth (ttm) | 851.37% |
Net Profit Margin (ttm) | -111.03% |
Return On Assets (ttm) | -38.42% |
EPS (ttm) | -1.12 |
PE Ratio (ttm) | -0.94 |
Dividend Yield | % |
Asset Description: | Seres Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
1.071 | 1.102 | 1.123 | 1.155 | 1.207 | 1.26 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |